Considerations for Innovator Drug Companies Regarding China’s Drug Patent Linkage System - 中国将施行药品专利链接制度——创新药企应如何应变
December 01, 2020
By Bruce M. Wexler, Melanie R. Rupert, Mi Zhou, Mark Sperling, & Jake Silvers
This article originally appeared in IP Economy magazine.
On June 1, 2021, China will implement a drug patent linkage system that will allow drug companies to resolve patent infringement disputes before the marketing approval of competitor drugs in China. Paul Hastings’ Global IP Co-Chair Bruce Wexler, Partner Melanie Rupert, and IP associates Mi Zhou, Mark Russell Sperling, and Jake Silvers, offer considerations for innovator drug companies in this rapidly developing area. A reprint is available at the link below.